Pharmaceuticals News and Research

RSS

Relationship of dialysis modality and mortality

For kidney disease patients who need to undergo dialysis, one type of treatment is not best for all, according to a study appearing in the January 2009 issue of the Journal of the American Society Nephrology (JASN).

17 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Antidepressants most common medicine for Australian women

A new study has revealed the most commonly prescribed medication for Australian women is antidepressants.

16 Dec 2008

Nutraceutix issued Australian patent

The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract.

16 Dec 2008

Both theories about human cellular aging supported by new research

Aging yeast cells accumulate damage over time, but they do so by following a pattern laid down earlier in their life by diet as well as the genes that control metabolism and the dynamics of cell structures such as mitochondria, the power plants of cells.

16 Dec 2008

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

14 Dec 2008

Exparel (DepoBupivacaine) shows promise in hernia repair

A Phase II trial of a single intraoperative administration of Exparel (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment.

14 Dec 2008

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

FDA to review Barr Pharmaceutical's BLA for adenovirus type 4 and 7 live oral vaccines

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review Duramed Pharmaceuticals, Inc.'s Adenovirus Types 4 and 7 Live Oral Vaccines Biologics License Application (BLA).

14 Dec 2008

Enzyme that mutates antibodies also targets cancer-causing gene

The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies.

12 Dec 2008

Enzyme that mutates antibodies also targets a cancer-causing oncogene

Rockefeller University scientists have discovered that the same enzyme that enables the immune system's defensive creativity is also responsible for a particular genetic malfunction - a translocation of one piece of DNA to the wrong chromosome - that causes Burkitt's lymphoma.

12 Dec 2008

An enzyme that mutates antibodies also targets a cancer-causing oncogene

11 Dec 2008

RNA interference can facilitate vaccine development

Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.

10 Dec 2008

Pralatrexate shows promise for T-Cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008

$Thiazolidinediones doubles risk of fractures in women$

Thiazolidinediones doubles risk of fractures in women

New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.

10 Dec 2008

Controlling the building blocks of life

A simple and reliable method for converting one of the simplest chemical entities into one of the most difficult-to-make molecular building blocks of life, with complete control over its shape, is reported by scientists at the University of Bristol in this week's Nature.

10 Dec 2008

Potential breakthrough for T-cell lymphoma

10 Dec 2008

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Researchers hunt for a hi-tech vaccine against Helicobacter pylori

Almost half of the world population is infected with bacteria Helicobacter pylori which colonizes stomach, causing gastritis and ulcers and is recognized by WHO as a type I carcinogen.

10 Dec 2008